500 MG FILM-COATED TABLETS
ZYTIGA® (abiraterone acetate) in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Consider what 730 fewer tablets* a year could mean for your patients with mCRPC.
See Prescribing Information for updated information.
The Janssen Commitment
For more than 30 years, Janssen Biotech, Inc., has delivered on the promise of new treatments and new ways to improve the health of individuals with serious disease.